https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/protein-responsible-rare-childhood-disorder-gives-clues-common-neurodegenerative-conditions/
Protein responsible for rare childhood disorder gives clues to common neurodegenerative conditions
9 Sep 2015, 4:10 p.m.
A new mutation in the protein STAT2 has been identified in patients with mitochondrial disease. These findings could also be beneficial for more common neurodegenerative diseases, including Alzheimer’s, Huntington’s and Parkinson’s diseases.Mitochondria are dynamic organelles that constantly go through elongation (fission), and shortening (fusion) in order to share their genetic material and contents. There is a delicate balance between these fission and fusion events, which are very important for normal cell function. Modulation of this dynamic can lead to mitochondrial disorders.
The team identified a novel mutation in a gene called STAT2, which codes for a protein involved in the innate immune system, in two children presenting with severe neurological deterioration following viral infection. The researchers also observed that the mitochondria of these two patients and a third unrelated STAT2-deficient patient, appeared abnormally elongated in shape. Through studying the function of these organelles in the lab, the researchers were able to show that one of the proteins involved in mitochondrial fission is inactive in cells that lack the STAT2 protein.
These findings imply that STAT2 is a novel regulator of mitochondrial fission. It is also the first study to link the innate immune system to mitochondrial function. It is hoped that new therapeutic targets for mitochondrial diseases can be developed from these findings, for which currently there are no effective cure.
This study was led by BRC-supported Professor Shamima Rahman and is published in Brain.
Young people donate tissue samples to unlock mysteries of arthritis
A new groundbreaking study led by researchers at the University of Birmingham, Great Ormond Street Hospital, University College London and Birmingham Children’s Hospital has revealed important clues into what is driving arthritis in children.
Toddler doing well after receiving newest gene therapy available on NHS
A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.
Genes may help to predict which children will respond well to arthritis treatment
A team of researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) have identified a set of genes that could be used to help doctors predict which children will respond well to treatment for juvenile idiopathic arthritis.
Making it easier to invest in frontline care
GOSH and UCL have signed a landmark agreement to simplify the commercialisation of any joint research and innovation and ensure any financial proceeds are shared equally.